PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.99 EUR | -0.17% | +2.57% | -35.00% |
Mar. 21 | Transcript : PHAXIAM Therapeutics S.A., Q4 2023 Earnings Call, Mar 21, 2024 | |
Mar. 20 | PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.00% | 19.69M | |
+3.08% | 108B | |
+9.41% | 104B | |
+6.32% | 23.66B | |
-11.55% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-13.68% | 16.19B | |
+4.69% | 13.72B | |
+33.93% | 12.22B |
- Stock
- Equities
- Stock PHAXIAM Therapeutics S.A.
- Stock PHAXIAM Therapeutics S.A. - Euronext Paris
- News PHAXIAM Therapeutics S.A.
- ECB, Bank of England Interest Rate Hikes Weigh Down European Equities